Incyte (INCY) Total Current Liabilities (2010 - 2026)
Incyte's (INCY) quarterly Total Current Liabilities came in at $1.3 billion in Q2 2026, up 2.62% YoY from $1.3 billion in Q2 2025, and down 11.92% on a QoQ basis from $1.5 billion in Q1 2026.
Incyte (INCY) Total Current Liabilities (2010 - 2026) Analysis & Trends
Incyte (INCY) has 17 years of Total Current Liabilities data on file, last reported at $1.3 billion in Q2 2026.
- Quarterly Total Current Liabilities rose 2.62% year-over-year to $1.3 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.3 billion (up 2.62% YoY) and the FY2025 annual result came in at $1.5 billion, down 7.72% from the prior year.
- Total Current Liabilities eased to $1.3 billion in Q2 2026, from $1.5 billion in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $1.7 billion in Q1 2025 to a low of $886.2 million in Q1 2022.
- A 5-year average of $1.3 billion and a median of $1.3 billion in 2025 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Current Liabilities jumped 42.04% — and 2026, when it slipped 13.41%.
- Tracing INCY's Total Current Liabilities over 5 years: stood at $1.2 billion in 2022, then gained by 7.2% to $1.2 billion in 2023, then soared by 32.37% to $1.6 billion in 2024, then fell by 7.72% to $1.5 billion in 2025, then retreated by 13.4% to $1.3 billion in 2026.
- The last three Total Current Liabilities figures came in at $1.3 billion (Q2 2026), $1.5 billion (Q1 2026), and $1.5 billion (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Incyte | 24.15 Bn | 19.61 Bn | 1.57 Bn | 1.31 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.31 Bn |
| Mar 31, 2026 | 1.49 Bn |
| Dec 31, 2025 | 1.52 Bn |
| Sep 30, 2025 | 1.34 Bn |
| Jun 30, 2025 | 1.28 Bn |
| Mar 31, 2025 | 1.72 Bn |
| Dec 31, 2024 | 1.64 Bn |
| Sep 30, 2024 | 1.50 Bn |
| Jun 30, 2024 | 1.34 Bn |
| Mar 31, 2024 | 1.40 Bn |
| Dec 31, 2023 | 1.24 Bn |
| Sep 30, 2023 | 1.12 Bn |
| Jun 30, 2023 | 1.12 Bn |
| Mar 31, 2023 | 1.01 Bn |
| Dec 31, 2022 | 1.16 Bn |
| Sep 30, 2022 | 1.01 Bn |
| Jun 30, 2022 | 926.67 Mn |
| Mar 31, 2022 | 886.16 Mn |
| Dec 31, 2021 | 854.31 Mn |
| Sep 30, 2021 | 742.71 Mn |